Using in Vivo Phage Display to Develop Targeted Therapy for Oral Ancer in Taiwan
Date Issued
2007
Date
2007
Author(s)
Cheng, Shi-Wei
DOI
zh-TW
Abstract
According to the 2003 annual cancer registry report of department of health, oral cancer ranks fourth in the mortality rate of male cancer patient in Taiwan. The surgery combine cytotoxic chemotherapy or radiotherapy is the major treatment as cancer therapies. These therapies are not specific for malignant cells and the efficiency is limited by serious side effect. Therefore, despite significant improvements in diagnosis, local management, and chemotherapy of head and neck cancer, there is no significant increase in long-term survival rates over the past 30 years. New treatment strategies are needed to improve the survival rates for oral cancer.
Recent studies show that in vivo phage display is a powerful tool for the discovery of ligands that selectively home to tumor. Using this method, we identify several 12-mer peptides specifically binding to xenografts of a Taiwanese oral cancer cell line TW2.6. One selected phage clone, TWO-5 specifically bound to the TW2.6 xenograft and the effects was inhibited by competition with phage-derived peptides. Furthermore, TWO-5-peptide-linked liposomes that carried doxorubicin (TWO-5P-Lipo-Dox) not only suppressed tumor growth better than Lipo-Dox but also showed no significant body weight change. TWO- 5P-Lipo-Dox treated mice have 100% survival rate but Lipo-Dox and PBS treated mice only have 66.67% and 33.33% survival rate. These results indicate that TWO-5 peptide enhanced the efficacy of the drug against oral cancer xenografts in SCID mice and suggest that this peptide has a strong clinical potential for drug delivery guider to treat oral cancer.
Subjects
噬菌體顯示法
口腔癌
標的治療
phage display
oral cancer
targeted therapy
SDGs
Type
other
File(s)![Thumbnail Image]()
Loading...
Name
ntu-96-R94450004-1.pdf
Size
23.31 KB
Format
Adobe PDF
Checksum
(MD5):6856f462f300fb036fffad3920c1c13b